Redirecting to https://www.prnewswire.com/news-releases/d3-bio-presents-kras-pipeline-updates-at-aacr-2026-elisrasib-d3s-001-a-next-generation-kras-g12c-inhibitor-shows-strong-phase-2-efficacy-across-multiple-tumor-types-302758218.html